Wire · regulatory
When the Primary Endpoint Moves After 283 Patients Are Already In
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
A primary endpoint amendment in a clinical trial after 283 patients have enrolled creates significant operational and regulatory challenges including IRB resubmissions, patient reconsent, data reconciliation, and increased site costs, despite protecting trial blinding and data integrity.
This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech.
◆ ◆ The Wire takeaway
You face a surge in hidden costs and operational risks once a clinical trial changes its primary outcome mid-execution. Plan now to manage IRB delays, patient communication, and data adjustments before budgets and timelines break.
◆ Coverage
1 source · 28 Sep 2026
◆ Related on Wire
◆ Topics